Pimavanserin (Nuplazid™)has been approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug’s manufacturer, Acadia Pharmaceuticals Inc., announced the approval on April 29. Pimavanserin is the first drug indicated specifically to treat symptoms of psychosis in Parkinson’s.

CONTACT US

Parkinson's Disease Research & Education Institute

Parkinson's Disease Research & Education Institute

               773 Grant St Calexico CA 92231 


Phone +17605405034

miguelmontano@rocketmail.com